Lung transplantation for end-stage cystic fibrosis before and after the availability of elexacaftor–tezacaftor–ivacaftor, Germany, 2012–2021
Felix C. Ringshausen, Annette Sauer‐Heilborn, T. Büttner, Anna‐Maria Dittrich, Nicolaus Schwerk, F. Ius, Lutz Nährlich, Tobias Welte, Mark Greer
Abstract
<b>This study observed a pronounced decline of CF-related lung transplants up to −83% in 2021 compared to the mean number in the period between 2012 and 2019, following the broad accessibility of elexacaftor-tezacaftor-ivacaftor in Germany in August 2020</b>https://bit.ly/3Pl7N9Y
Topics & Concepts
IvacaftorCystic fibrosisLung transplantationMedicineStage (stratigraphy)LungInternal medicineOncologyBiologyPaleontologyCystic fibrosis transmembrane conductance regulatorCystic Fibrosis Research AdvancesTransplantation: Methods and OutcomesTracheal and airway disorders